Abstract | Neurotoxicity caused by traditional chemotherapy and radiotherapy is widely recognized in patients with cancer. The adverse effects of newer therapeutics, such as biological and immunotherapeutic agents, are less well established, and are associated with considerable neurotoxicity in the central and peripheral nervous systems. This Review addresses the main neurotoxicities of cancer treatment with a focus on the newer therapeutics. Recognition of these patterns of toxicity is important because drug discontinuation or dose adjustment might prevent further neurological injury. Knowledge of these toxicities also helps to differentiate treatment-related symptoms from progression of cancer or its involvement of the nervous system. Familiarity with the neurological syndromes associated with cancer treatments enables clinicians to use the appropriate treatment for the underlying malignancy while minimizing the risk of neurological damage, which might preserve patients' quality of life.
Neurotoxicity that arises from cancer treatment has been widely recognized. Chemotherapy or radiotherapy can have important effects on the central or peripheral nervous systems, which can limit the course of treatment 1 . Common adverse effects of cancer treatment include chemotherapy-induced peripheral neuropathy and radiation-induced cognitive dysfunction, which result from direct damage to neurons and their surrounding microenvironment 2, 3 . With the development of biological and immunotherapeutic agents to treat cancer, new patterns of neurotoxicity have emerged that are less well described. For example, cerebrovascular events can occur due to alterations in the vasculature by antiangiogenic agents 4 and autoimmune neurological dysfunction may can result from upregulation of the immune system induced by immunotherapeutic agents 5 . Given the protection of the blood-brain, bloodcerebrospinal fluid (CSF), and blood-nerve barriers, and the low proliferative rate of neurons, the nervous system should be relatively protected from the toxic effects of chemotherapy and radiotherapy; however, neurotoxicity is second only to myelosuppression as the dose-limiting factor of cancer treatment 6 . The occurrence of nervous system toxicity depends on a variety of factors that include the dose of treatment delivered, route of administration, interactions with other agents, presence of underlying structural nervous system disease, and individual patient vulnerability -most of which are poorly understood 7 . Treatment toxicity can occur as a result of direct damage to neurons or glia, or indirectly by altering the surrounding neuronal microenvironment, owing to localized vascular injury, for example 8 . Typically, no confirmatory test is available for the diagnosis of neuro toxicity, and the attribution of symptoms to treatment toxicity is largely a diagnosis of exclusion, but recognition of neurological adverse effects is important because dose adjustment or treatment discontinuation can prevent further injury 1 . We review the main neuro toxic effects of cancer treatment with a focus on the newer therapeutics, such as targeted anticancer agents and immunotherapies, as their adverse effects are less familiar. We discuss each symptom that patients with cancer-treatment-induced neurotoxicity experience and how with when they present to their clinicians. We also highlight how these symptoms should be managed to reduce permanent neurological injury.
Background
Traditional chemotherapy preferentially acts on dividing cells by inducing DNA damage and strand breakage, interfering with DNA repair and microtubule function. These mechanisms are, however, nonspecific and can result in damage to normal cells. Because the nervous system was thought to be static and not to contain dividing cells, it was assumed that the nervous system would be spared injury. However, that the central nervous system (CNS) contains stem cells that replenish some neuron populations and that glia divide, albeit slowly, is now clear 9 . Thus, the CNS is an unexpected target of drugs that affect dividing cells.
Biological therapy includes treatments that exploit the immune system to recognize and fight cancer cells. Such treatments include antibodies against receptors that are involved in cell growth and cell division, such as cetuximab, and angiogenesis, such as bevacizumab; agents that upregulate the host immune system, such as ipilimumab; and therapies that directly target speci fic mutations or expressed proteins harboured by tumour cells, such as blinatumomab. Neurological toxi city can result from a heightened immune response and crossreactivity with cells of the nervous system because of the action of these newer agents on the host immune system 5 . Radiation therapy, similar to chemotherapy, targets dividing cells and can cause damage to neural structures directly or indirectly by causing vascular damage, endocrine disturbance, and fibrosis of neural structures 10 . These effects are usually delayed by weeks to years after therapy, reflecting the slow rate of cell turnover in the nervous system. Adverse effects of radiotherapy typically depend on the total dose used, the dose per fraction, the total volume irradiated, and comorbid conditions 11 .
Complications of the CNS Headache
Headache is one of the most-common complications of cancer treatment. Patients with a history of headache before treatment might be more susceptible to this complication following treatment; however, all patients are at risk of developing headache due to treatment. Headache has been associated with the use of several chemotherapeutic agents (BOX 1) . The mechanisms of headache development are largely unknown, but headache occurs more frequently with agents that penetrate the blood-brain barrier, particularly temozolomide, nelarabine, and either intrathecal or high-dose intravenous methotrexate 8 . Headache occurs with biological treatments as well, such as during administration of rituximab, a human monoclonal antibody targeting CD20-positive cells that is commonly used in the treatment of lymphoma. Typically, the headache associated with rituximab starts within hours of the infusion and is mild-to-moderate in severity. Headache is not usually a dose-limiting toxicity of this treatment 12 . Patients can experience headache during and shortly after the first infusion of trastuzumab for treatment of HER2-positive breast cancer. The headache can persist for several days and usually decreases in intensity over subsequent infusions [13] [14] [15] . Case reports of trastuzumab-induced migraine headache exist, although this syndrome seems to be rare 16 . In a study of 420 patients receiving cetuximab, an anti-EGFR antibody, for the treatment of advanced-stage colorectal cancer, 26% developed headache 17 . This symptom is also seen with administration of chimeric antigen receptor (CAR) T cells, a new immunotherapy used for the treatment of B-cell malignancies 18 . The neurotoxicity associated with this treatment is probably related to the markedly elevated levels of inflammatory cytokines that accompany the transfer of these CAR T cells to patients 19 . Treatment with steroids can reduce these inflammatory changes, but also compromises the efficacy of the CAR T cells against the malignancy; therefore, the use of steroids to negate headache is often restricted. Interferons (IFNs) 20 and interleukins 21 are other immunotherapies that have been reported to be associated with headache.
Cancer treatment can also induce intracranial processes that result in headache. Headache might be a manifestation of aseptic meningitis, which is common after intrathecal treatment with any chemotherapy or biological therapy, including steroids 8 . Patients typically present within hours of drug administration with headache, nausea, neck stiffness, fever, and lethargy, and are found to have a CSF pleocytosis with a negative CSF bacterial culture 22 . The chemotherapeutic agents that most commonly cause aseptic meningitis after intrathecal administration are cytarabine, methotrexate, thiotepa, and topotecan 23 . Dexamethasone treatment should be given prophylactically with intrathecal use of the liposomal preparation of cytarabine, as 40% of patients will develop clinically significant aseptic meningitis with this agent 24 . Ipilimumab, the cytotoxic T-cell lymphocyteassociated protein 4 (CTLA-4) inhibitor used to treat metastatic melanoma, can also induce aseptic meningitis. Ipilimumab binding to CTLA-4 blocks inhibitory feedback signalling by this receptor in T cells, which leads to a highly activated T-cell response that can act on the patient's own tissues in addition to the tumour, resulting in inflammation of several organ systems 5 . In the case of aseptic meningitis, diagnostic work up usually reveals elevated CSF protein levels and mild pleo cytosis, as well as contrast-enhancement of the meninges on MRI of the brain 5 . Aseptic meningitis in most patients improves with steroid treatment.
Retinoid treatment can cause headache by inducing idiopathic intracranial hypertension (pseudo tumour cerebri), with an elevated CSF opening pressure in the absence of a space occupying lesion in the brain. Headache can sometimes occur in these patients even when intracranial pressure is not demonstrably elevated.
An acute toxicity of radiotherapy to the brain is headache secondary to disruption of the blood-brain barrier. This effect is most common with the use of daily radiation fractions greater than 300 cGy and in those patients with large intracranial lesions that have substantial associ ated oedema 10 . Glucocorticoids can be used to both prevent and treat this problem.
Key points
• Cancer treatments are associated with substantial neurotoxicity, which is a diagnosis of exclusion • Treatments affect both the central and peripheral nervous systems • Biological and immunological therapies have different mechanisms of toxicity • Recognition of neurotoxicity is important to prevent further neurological injury and to distinguish this toxicity from nervous system involvement of cancer
Seizures
Seizures can occur after treatment with a variety of intravenous chemotherapeutic agents
. For agents such as high-dose busulphan, the risk of seizure is high and antiepileptic medication for seizure prophylaxis is recommended. Seizures can be nonc onvulsive in nature and can manifest as encephalopathy with nonconvulsive status epilepticus demonstrated on electro encephalogram (EEG). Seizures might be related to the chemotherapeutic agents themselves, or as a result of microenvironmental changes induced by therapy. For example, vincristine can induce a syndrome of inappropriate antidiuretic hormone (SIADH) secretion that can cause hyponatraemia and subsequent seizure activity 25 . Seizures are more common with intrathecal administration of chemotherapy than oral or intravenous administration, particularly with cytarabine, methotrexate, and rarely topotecan 26 .
Immunomodulatory agents, such as IFN and IL-2 can cause seizure activity. Owing to the cytokine storm induced by the administration of CAR T cells, seizures are common in patients receiving this treatment and can be difficult to control. Prophylactic antiepileptic medication can be used to prevent onset of seizure activity; however, if seizures result, a combination of several antiepileptic agents and steroids is typically required to control seizure activity. Other immunotherapy agents, such as blinatumomab, a bi-specific T-cell engager (BiTE) antibody that reacts with normal CD3-positive T cells and CD19-positive acute lymphocytic leukaemia cells, causes seizures in 15-20% of treated patients 6 . The most-common presenting symptom of posterior reversible encephalopathy syndrome (PRES) is seizure, which is described in more detail later in this Review.
Acute encephalopathy
Acute altered mental status is the most-common CNS toxicity observed after a number of cancer treatments
. Manifestations include impaired attention, confusion, and altered level of alertness ranging from drowsiness to stupor. Somnolence alone is a manifestation of acute encephalopathy and can be a specific toxicity of some drugs, such as thalidomide, which can cause somnolence within hours of administration and can take 2-3 weeks to resolve; it can also be a delayed effect, for example, somnolence has been noted to occur 1 week after administration of nelarabine 27 . Acute encephalopathy occurs commonly after the use of cancer treatments that can penetrate the bloodbrain barrier, such as high-dose cytarabine or methotrexate, nitrosoureas, and procarbazine; however, many other agents can induce acute encephalopathy
. The encephalopathy usually improves with drug withdrawal, but on rare occasions can require an antidote for reversal. For instance, the encephalopathy seen after administration of ifosfamide usually occurs within 12 h to 6 days after drug administration, and while it might improve without intervention, administration of intravenous methylene blue typically shortens the duration of symptoms 28 . Several of the small-molecule inhibitors used to treat cancer, such as sunitinib and bortezomib, and immunotherapeutic agents, such as blinatumomab and CAR T-cell infusion, are associated with acute changes in mental status that are usually reversible 29, 30 . At high doses, IFN-α that is used to treat low-grade lymphoma, chronic myeloid leukaemia, multiple myeloma, melanoma, Kaposi sarcoma, and hairy-cell leukaemia can cause marked changes in mental status 31 . Patients often become lethargic, confused, and develop hallucinations. Typically, these symptoms subside with drug withdrawal, but they can progress to a chronic dementia or vegetative state 20 . At lower doses, patients might develop neuropsychiatric symptoms that manifest as depression and cognitive slowing 32 , which usually remit several weeks after discontinuing the medication. IL-2 is sometimes used with IFN in the treatment of renal-cell carcinoma and melanoma, and can induce similar dose-dependent neuropsychiatric symptoms in 30-50% of patients 31 . These symptoms include depression, hallucinations, and cognitive changes; symptoms usually resolve with cessation of treatment 33 . Cranial radiation can cause specific syndromes of encephalopathy depending on the proximity of the clinical symptoms to the treatment. Acute radiationinduced toxicity occurs hours to days following the delivery of large fractions of radiation to the brain (typically greater than 300 cGy), particularly in patients with elevated intracranial pressure 34 . This treatment can cause an acute encephalopathy with headache, confusion, and lethargy that can be prevented and treated with cortico steroids. Acute delayed radiation-induced encephalo pathy occurs weeks to months after cranial radiation for a cerebral tumour, and is thought to be a consequence of demyelination 34 . This adverse effect often causes worsening focal symptoms and signs that reflect the cerebral location of irradiation. Imaging shows worsening enhancement in the area of treated tumour, which can be impossible to differentiate from tumour pro gression 35 . In patients with glioblastoma, this observation is often referred to as pseudoprogression, but it can be seen in any patient receiving focal radiotherapy for an intra cranial lesion. Radiation somnolence syndrome is a specific acute delayed radiation reaction, characterized by sleepiness in the absence of focal neurological deficits and usually without evidence of elevated intracranial pressure; it occurs 1-6 months following brain radiotherapy and is more commonly seen in paediatric patients than in adults 36 . The syndrome usually resolves spontaneously in a matter of weeks. Corticosteroid use can prevent somnolence syndrome, but does not reverse the symptoms once they develop. The acute and early-delayed mental status changes, which occur within the first 6 months of radiotherapy resolve over weeks to months and do not result in permanent disability. Most importantly, these syndromes do not predispose to late-delayed neurotoxicity that starts more than 6 months after radiotherapy is completed, which is associated with irreversible cerebral injury, as discussed below.
Chronic encephalopathy
Chronic mental status impairment and structural brain changes, such as leukoencephalopathy, develop months to years after receiving cancer-directed therapy to the CNS. Clinically, these patients present with slowly progressive cognitive dysfunction and personality change 37 . Radiographically, diffuse periventricular white matter changes are observed on MRI scans of the brain, sometimes with areas of focal enhancement, cerebral atrophy, and ventricular dilation (FIG. 1) . These changes can lead to severe weakness, dementia, coma, and death.
Chemotherapy can cause leukoencephalopathy or can potentiate the toxicity associated with cranial radiotherapy, regardless of the sequence of the two modalities. This effect has been best studied with metho trexate 38 ; however, dementia might occur in patients receiving carmustine, cytarabine, fludarabine, thalidomide, tumour-necrosis factor α (TNFα), or vincristine 39 . Any intrathecal drug, including rituximab and topotecan, can lead to chronic encephalo pathy. Rarely, capecitabine causes multifocal leukoencephalopathy 40 .
In addition to overt cognitive changes, some patients with cancer experience more-subtle effects of cognitive dysfunction after receiving cancer treatment 41 . After chemo therapy, these changes are commonly referred to as 'chemobrain' and many studies report subtle impairment in executive function, processing speed, and memory in patients who have received treatment, particularly with high-dose chemotherapy regimens 7 . Cognitive deficits are more likely to be permanent if they are associated with structural changes in the brain, as observed on MRI. Radiotherapy to the brain, particularly whole-brain radiation, commonly leads to diffuse cerebral atrophy that usually begins within 6 months of completing treatment. Atrophy can be asymptomatic or present as memory loss, gait abnormalities, and incontinence, similar to the syndrome of normal-pressure hydrocepha lus. Patients can derive benefit from ventriculoperitoneal shunt placement, although only partial reversal of symptoms is observed, primarily improved bladder control and gait stability. Elderly patients who have received whole-brain radiotherapy are most susceptible to this syndrome.
Radiotherapy to the brain can also cause a late-delayed mild cognitive impairment in contrast to frank dementia. Cognitive decline can manifest by impairments in working memory, verbal memory, and general intelligence quotient 42 . These clinical findings have been confirmed in animal models, with dose and time-dependent deficits in cognitive function seen in rats after receiving whole-brain radiotherapy 43 . Hippocampal neurogenesis can be affected by cancer treatment and is one potential cause of mild cognitive change 44 . The subgranular zone of the dentate gyrus in the hippocampus is one of the main regions of ongoing neurogenesis in the adult brain 9 . Hippocampal stem cells and progenitor cells contribute to neuron production in the hippocampus. With exposure to an enriched environment and exercise, neurogenesis can be increased in this region; however, memory loss and cognitive deficits can result from disruption of hippocampal neuro genesis. Chemotherapy, radiotherapy, and inflammatory states can interrupt hippocampal neurogenesis 45, 46 . Radiotherapy inhibits the generation of new hippocampal granule-cell neurons and causes changes in the surrounding microenvironment, producing a proinflammatory state that leads to further interruption of neurogenesis 47, 48 . Negating this effect is the basis for the use of hippocampal-avoidance whole-brain radiotherapy to treat multiple brain metastases. This approach can effectively treat the multiple sites of metastases without compromising cognition, by sparing the region of hippocampal neurogenesis 49 ; this technique is currently under investigation in a randomized phase II trial 50 . An alternative possible mechanism of damage underlying cognitive change due to anticancer therapy is demonstrated by preclinical data that indicate toxicity to CNS progenitor cells and nondividing oligodendrocytes after exposure to 5-fluorouracil in mouse models, leading to delayed damage of myelinated white-matter tracts 51 . This mechanism of damage occurs independently of inflammation and vascular damage. Similar toxicity to oligodendrocyte progenitors and neural stem cells in the subventricular zone has been demonstrated in rats after exposure to radiotherapy to the brain, suggesting that this mechanism makes an important contribution to delayed CNS toxicity from cancer therapies 52 . In patients, white-matter destruction is identified routinely using fluid-attenuated inversion recovery (FLAIR) sequences on MRI and can be further detected, and to some extent quantitated, by diffusion tensor MRI (DTI), which assesses the integrity of the white matter in the brain 53 . Another specific, but rare, aetiology of chronic mental status change is progressive multifocal leukoencephalopathy (PML), a fatal demyelinating disease caused by activation of latent John Cunningham (JC) virus 54 . The risk of PML increases with administration of highly immunosuppressive agents, such as fludarabine 55 . The risk is greater in elderly patients or those receiving treatment that induces chronic immunosuppression. The drugs usually associated with a risk of PML include agents that target B-cells, such as rituximab 56 , alemtuzumab (CD52 inhibitor) 57 , and brentuximab (CD30 inhibitor) 58 . In addition, the diseases for which these agents are used, such as chronic lymphocytic leukaemia, are independently associated with PML and, therefore, the combination of longstanding disease and drug administration might lead to the development of PML. No effective treatment exists for this condition other than efforts to reconstitute the immune system by withdrawal of the causative agents.
Posterior reversible encephalopathy syndrome
Several different types of cancer treatment can cause PRES
. Patients with this syndrome present with headache, confusion, visual changes, and seizures. The MRI has a typical appearance of bilateral white-matter Nature Reviews | Clinical Oncology lesions seen on MRI FLAIR sequences, with predominance in the posterior circulation, affecting the parietal and occipital lobes (FIG. 2) . The exact aetiology of PRES is unclear, but is thought to be related to failure of autoregulation of cerebral blood pressure and endothelial dysfunction 27 . Normally, cerebral auto regulation is maintained by arteriole dilation and constriction, allowing the cerebral blood flow to remain constant across a range of systemic blood pressures. If systemic blood pressure exceeds the upper limit of autoregulation, hyper perfusion of the brain can occur, which results in breakdown of the blood-brain barrier and extravasation of fluid into the brain 59 . In patients with chronic hypertension, the range of autoregulation shifts to accommodate a higher range of systemic blood pressure. When such patients develop an acute increase in blood pressure that exceeds the upper limit of the ability to compensate in order to maintain constant cerebral blood flow, they are at risk of PRES. Therefore, PRES is usually seen in the setting of acute hyper tension (sometimes treatment-induced), and whether PRES can be induced directly by a chemotherapeutic agent or whether the associated blood-pressure elevation was missed in those with near normal blood pressure at symptom onset remains unclear. Alternatively, endothelial dysfunction can result as a direct effect of cytotoxic therapy, which releases molecules that cause disruption of the bloodbrain barrier, capillary leakage, and axonal swelling and might trigger vasogenic oedema [60] [61] [62] . In this proposed mechanism, hypertension does not have to accompany PRES. These mechanisms are not m utually exclusive and both can contribute to PRES.
PRES is seen more commonly in patients receiving cyclosporine and cyclophosphamide than in patients receiving cisplatin, cytarabine, gemcitabine, ifosfamide, and vincristine 63 . Immunomodulatory agents used to treat graft-versus-host disease in allogeneic stem-cell transplant recipients, such as tacrolimus, are a common aetiological factor for PRES. Bevacizumab, ipilimumab, sorafenib, sunitinib, and rituximab are associated in PRES in less than 1% of treated patients 64 . Hypertension caused by these agents is often volatile and any indication of increasing blood pressure requires tight bloodpressure monitoring and control; the patient might have only mild elevation of blood pressure at presentation and the spikes in blood pressure are often missed at diagnosis. Once PRES develops, discontinuation of the causative agent is essential, and the clinical and radiographic changes associ ated with this syndrome are usually reversible, unless cerebral infarction has occurred. Antiepileptics are recommended if PRES is associated with seizure activity and treatment should be continued until radiographic changes resolve.
Cerebrovascular disease
Patients with cancer have an increased risk of stroke and other cerebrovascular disease due to the underlying hypercoagulability associated with malignancy as well as the treatments they receive; chemotherapeutic agents that include l-asparaginase, cyclosporine, doxorubicin, estramustine, methotrexate, and platinum-based treatments all slightly increase the risk of stroke [65] [66] [67] . The risk of cisplatin-induced stroke increases if the drug is used in combination with other chemotherapeutic agents 7 , although the exact pathophysiology underlying this effect is unknown. High-dose methotrexate can induce a 'stroke-like' syndrome of reversible and fluctuating neurological symptoms 68 . Ipilimumab induces inflammation of the large blood vessels consistent with a giantcell arteritis that increases the risk for stroke 69 . MRI of the brain in patients treated with agents associated with stroke can reveal changes on diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) sequences that indicate ischaemia, and slowing on EEG can be evident 70 . These clinical and radiographic findings are usually reversible over time and the patient is typically left without neurological deficit. In addition to arterial thrombosis, chemotherapeutic agents such as l-asparaginase increase the risk of venous sinus thrombosis 71 , which can lead to stroke, intracranial haemorrhage, and seizures. Bevacizumab substantially increases the risk of cerebrovascular thrombosis as well as intracranial haemorrhage, particularly in patients with prior history of thrombotic events. The proposed pathophysiology of these events is the endothelial-cell changes induced by inhibition of VEGF that lead to increased permeability and thrombosis of newly formed tumour-associated blood vessels 72 . In a large retrospective review of 17,466 adverse events reported with bevacizumab from November 1997 to May 2009, 154 of these events were intracerebral haemor rhage that occurred in 99 patients 4 . Of these patients, 16 had brain metastases and 13 had known primary brain tumours 4 . These patients had received a median of three doses of bevacizumab (range 1-36 doses) before the haemorrhage occurred 4 . Death was associated with intracranial haemorrhage in 33% of the 99 patients who suffered an intracranial haemorrhage 4 . The risk of haemorrhage was increased for those patients receiving concurrent antiplatelet and anticoagu lation treatment 4 . In another cohort of 210 patients enrolled in phase II trials of bevacizumab for malignant glioma, 1.9% experi enced intraparenchymal brain haemorrhage and 9% of patients suffered thrombotic events, including stroke 73 . In this study 73 , the probability of haemor rhage and thrombotic events increased with duration of bevacizumab treatment. Thus, the incidence of stroke and intracerebral haemorrhage is relatively low in patients treated with bevacizumab, although these neurological complications can be the cause of considerable morbidity and mortality. A meta-analysis of 20 randomized trials of bevacizumab-based treatment demonstrated an increased relative risk of 1.46 for ischaemic stroke 74 . Radiotherapy to the brain and neck can induce a delayed vasculopathy with accelerated atherosclerosis, which increases the risk of stroke, but this increased risk manifests years after treatment 75 . Aside from acceleration of atherosclerosis and cerebrovascular disease, cavernomas can occur many years after cranial or spinal radiation therapy 76 . These cavernomas have a higher risk of bleeding than those not associated with radiotherapy (FIG. 3) . In addition to haemorrhage, cerebral cavernomas can cause seizures 77 . Similarly, radiation to the chest, neck, or spine might cause spinal cord telangiectasias that can result in spinal cord haemorrhage 11 . These patients usually present with the sudden onset of back pain and leg weakness that resolves over weeks to months.
Cerebellar dysfunction or ataxia
Cerebellar dysfunction presents with nystagmus, dysarthria, confusion, scanning speech, and ataxia. The most common chemotherapy to induce a cerebellar syndrome is high-dose cytarabine, usually at cumulative doses greater than 36 g/m 2 (REFS 28,78); 10-25% of patients treated with high-dose cytarabine will be affected 79 . The cerebellar dysfunction is usually more pronounced in elderly patients and in those with preexisting neurologi cal conditions or renal dysfunction. Fortunately, most of the symptoms resolve within 2 weeks of discontinuing treatment, but some patients have permanent impairment secondary to loss of Purkinje cells in the cerebellum 80 . Despite marked symptoms of cerebellar dysfunction in some patients, imaging results are usually normal; however slowing seen on EEG can be observed. Other chemotherapeutic agents that can induce cerebellar dysfunction include capecitabine, 5-fluorouracil, hexamethylmelamine, nelarabine, oxaliplatin, pro carbazine, and vincristine 81 . Blinatumomab rarely induces cerebellar syndrome: the prevalence of this adverse event was 2 of 95 patients in one cohort, and the syndrome was reversible with discontinuation of the drug 6 . Patients also report nonspecific dizziness with administration of cyclophosphamide, methotrexate, bortezomib, or rituximab; whether this symptom is a direct cerebellar or vestibular effect of these drugs is unknown.
Movement disorders
Abnormal movements can be seen with use of many of the supportive agents that accompany the administration of cancer treatments, including antiemetics. Metoclopramide, a common antiemetic used to treat chemotherapy-induced nausea, is a dopamine receptor antagonist, predominantly of the D2 receptor 82 . Normally, direct activity in the nigrostriatal pathway and indirect activity of the striatopallidal pathway are balanced within the basal ganglia to regulate movement. Inhibition of the D2 receptors in the striatopallidal projection can lead to imbalance of these inputs resulting in abnormal movements with chronic use 82 . Patients can experience dystonic reactions that might require anticholinergic treatment. Within the first 3 months of chronic use, patients can experience akathisia (restlessness requiring the need for constant movement) and parkinsonism (tremor, bradykinesia, and rigidity). These adverse effects are usually reversible with discontinuation of the medication. Chronic treatment with meto clopramide might induce tardive dyskinesia, a syndrome of involuntary Nature Reviews | Clinical Oncology and repetitive movements, usually involving the lower face. Tardive dyskinesia usually manifests by tongue protrusion, lip smacking, lip pursing, and grimacing. Unfortunately, despite drug discontinuation, the condition can sometimes persist. The risk of developing tardive dyskinesia with chronic use of dopamine-blocking agents ranges from 1-10% 83 . For this reason, other types of antiemetics, such as 5-hydroxy tryptamine receptor antagonists, which have a much lower risk of causing tardive dyskinesia, are preferred. The 5-hydroxytryptamine receptor antagonists, such as ondansetron, can also cause acute dystonic reactions and extrapyramidal symptoms, but less commonly than meto clopramide. Tremor is another movement disorder that may be caused by a variety of chemotherapeutic agents, such as nelarabine and IFN-α, and can occur with steroid use. Vincristine may cause parkinsonism and athetosis.
Other radiation therapy CNS syndromes Radiation necrosis. Most adverse effects that are specifically related to radiotherapy usually result from direct radiation to the CNS or are a consequence of CNS tissue being unavoidably included in a radiotherapy port. For instance, radiation necrosis usually occurs 1 to 2 or more years after radiotherapy to a primary or secondary brain tumour or might develop in a temporal lobe that was irradi ated during treatment for a head and neck neoplasm 84, 85 . Symptoms including aphasia, hemiparesis, and seizures are dependent on the region of the brain involved, and are often suggestive of a recurrent or new tumour in the brain. MRI shows extensive T2/FLAIR changes and contrast-enhancement that can mimic the original tumour or be confused with a new site of disease. Typically, lesions are hypometabolic on 18 F-fluorodeoxyglucose-PET and are unlikely to have elevated plasma volume on MR perfusion imaging, but these techniques do not always enable differentiation of the tumour from radiotherapy necrosis. Treatment includes corticosteroids, bevacizumab, and sometimes surgical resection, which can also provide definitive diagnosis 86 .
SMART syndrome. Stroke-like migraine attacks after radiotherapy, known as SMART syndrome, occur within 1-30 years or more after brain radiotherapy 87 . Patients can present with episodic focal neurological symptoms and seizures. MRI can show focal enhancement at the time of the event, although these changes typically resolve as the syndrome is likely related to neuronal dysfunction rather than cerebral vascular compromise 88 . Repeated episodes can be prevented by drugs that are effective agents for migraine prophylaxis, such as valproic acid.
Secondary malignancies
Prior radiotherapy to the central or peripheral nervous systems can cause secondary tumours including meningio mas, gliomas, malignant schwannomas, and sarcomas. These malignancies can occur even with lowdose radiation, as they have been seen after treatment of tinea capitits with 100-200 cGy whole-brain radiotherapy 89 . Secondary tumours are more likely to occur after traditional radiotherapy; however, they can also develop after stereotactic radiosurgery 90, 91 . The delay to tumour diagnosis is often many years, even decades, after the radiotherapy. The tumours are usually of a high-grade variety, and full treatment of these secondary tumours is often compromised by previous radiotherapy in light of concerns about the total dose of radiation to which the brain is exposed.
Cranial neuropathy
A variety of drugs can induce specific cranial neuropathies; the causes are either idiosyncratic or part of a more-diffuse peripheral neuropathy resulting from treatment with a drug such as vincristine. Radiotherapy can also cause cranial nerve injury when the nerve is included as part of a therapeutic port (TABLE 1) .
Spinal cord syndromes
Myelopathy usually causes lower extremity weakness, sensory change, and alterations in bowel and bladder control; back pain might or might not be a feature. These symptoms occur after intrathecal administration of any chemotherapeutic agent, such as methotrexate, cytarabine, or thiotepa. Symptoms can start within minutes, but can also have delayed onset of up to 2 weeks after administration. The risk of myelopathy is higher in patients who have received prior spinal radio therapy 23 .
Myelopathy from intravenous chemotherapy is less common than with intrathecal treatment, but can occur with cisplatin. Cisplatin and oxaliplatin can cause transient demyelination of the cervical spinal cord with normal imaging. Patients with cisplatin-induced demyelin ation may experience transient electric shock-like sensations radiating down the spine or into the limbs with flexion of the neck, known as Lhermitte phenomenon 92 . Lhermitte phenomenon can arise after radiotherapy to the neck as an early adverse effect. In both circumstances, the symptom is temporary and does not predict permanent spinal cord injury.
Radiation-induced myelopathy occurs as a late-delayed effect of treatment and usually starts as a painless Brown Séquard syndrome of crossed motor and sensory deficits below the site of injury (ipsilateral weakness and proprioceptive deficits and contralateral pain and temperature sensory loss) with progression to paraparesis and even quadriparesis over the weeks to months following onset. MRI findings are usually nonspecific, however, in the early stages of radiation-induced myelopathy, the spinal cord can be swollen and show contrast-enhancement with gadolinium on MRI and, at later stages, the cord is atrophic. Unfortunately, no effective treatment is available for radiation-induced myelopathy, although steroid administration might delay progression. Reports of benefit from hyperbaric oxygen and anticoagulation therapy have not been validated and whether bevacizumab might have efficacy in this setting is unknown, although this agent has been reported to provide benefit for patients with cerebral radiation necrosis 86, 93, 94 . Ipilimumab can induce inflammation of the spinal cord resulting in an acute transverse myelitis. Patients present with sensory, motor, and bowel and bladder changes below a spinal cord level, usually in the thoracic cord. MRI of the spine might demonstrate T2 signal change at the affected spinal cord level and CSF analysis often shows a pleocytosis and elevated protein level without evidence of malignant cells, infection, or other inflammatory processes. In one patient, symptoms started a week after ipilimumab treatment, and when treatment was withheld and high-dose steroids were administered, the patient improved within 2 weeks 95 .
Peripheral nervous system complications Plexopathy Two major plexuses of peripheral nerves can be affected by cancer treatment: the brachial plexus that innervates the arm and involves spinal roots C5-T1, and the lumbosacral plexus that innervates the leg and involves spinal roots L1-S3. A plexopathy manifests by a combination of weakness, sensory impairment, and reflex abnormalities with or without pain involving multiple nerve roots innervating the affected limb. This syndrome is rarely induced by cytarabine, IFN-α, and IL-2, but is more commonly seen as either an early-delayed or a late-delayed effect of radiotherapy that is typically painless 96 . Brachial plexopathy is common after radiotherapy to the chest wall for treatment of breast or lung cancer 97 , whereas lumbosacral plexopathy can arise after radiation delivery to the pelvic region. Radiationinduced plexopathy is usually associated with total radiation doses greater than or equal to 5,000 cGy, but can be seen with lower doses as well 98 . Clinical diagnosis can be supported by electrodiagnostic testing that demonstrates segmental slowing on nerve conduction studies, fasciculations and myokymic discharges on electro myography (EMG), which are specific for the condition but present in only about 60% of patients 99 . CT or MRI can show diffuse loss of tissue planes and occasionally fibrosis, which can be confused with tumour diagnosis if sufficiently bulky, but PET imaging characteristically shows hypometabolism. The brachial plexus is more-commonly affected than the lumbosacral plexus. Delayed damage to these plexuses can be slowly progressive over many years and is thought to be related to damage of the Schwann 
• Dry eye syndrome, cataract, glaucoma, retinopathy, optic neuropathy (begins 7-26 months after radiation therapy, painless, monocular or bilateral blindness, papilloedema and retinal haemorrhage can be present)
Extraocular palsy
• Cytarabine • Vincristine • Interferon-α • Rare • Can be isolated or occur with other cranial neuroapthies • NA Ptosis • Vincristine • Can be unilateral or bilateral Facial weakness • Vincristine • Vemurafenib • Isolated case reports of peripheral facial nerve palsy, sometimes bilateral Hearing loss • Carmustine • Cisplatin • Vincristine
• Oxaliplatin
• Radiotherapy (to head or ear)
• Intra-arterial administration • Hair-cell damage 148 cells 100 . Unfortunately late injury to these plexuses is usually p ermanent and disabling.
Peripheral neuropathy
Peripheral neuropathy is the most-common neurological complication of cancer treatment and can be a doselimiting toxicity, particularly in elderly patients. The incidence of chemotherapy-induced peripheral neuropathy (CIPN) in patients treated with multiple chemotherapeutic agents is approximately 38% 101 . Most CIPNs present with a symmetric, length-dependent 'stocking and glove' distribution of sensory, rather than motor, abnormalities; they are typically axonal in pathophysiology and sensory axonal damage can be identified with reduced sensory nerve action potentials on nerve conduction studies 102 . Many traditional chemotherapies cause peripheral neuropathy (TABLE 2) 2,27, [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] . All of these drug-induced neuropathies can be enhanced by pre-existing or new peripheral neuropathy from a non-cancer-related cause, such as diabetes or alcohol, or might be amplified by the sequential or combined use of neurotoxic agents, such as vinorelbine following a platinum-based treatment.
Several neuroprotective strategies that include calcium and magnesium supplementation, and administration of acetyl-l-carnitine, amifostine, amitriptyline, diethyldithiocarbamate, erythropoietin, glutamine, nimo dipine, all-trans-retinoic acid, and vitamin E have been suggested to prevent CIPN without compromising the treatment effect; however, clinical trials examining the effectiveness of these agents have been negative 120, 121 . Given the lack of evidence supporting these prevention strategies, ASCO recently published guidelines that recommend against the use of these agents 122 . Limited evidence suggests that glutamine could help prevent neuropathy associated with paclitaxel and oxaliplatin treatment 123 . The ASCO guidelines make no recommendations about the use of N-acetylcysteine, carbama zepine, glutamate, and glutathione for patients receiving platinum-based therapies. More recently, specific genetic polymorphisms inherent to the patient have been demonstrated to enhance or reduce vulnerability to individual CIPN, and tailoring the drug dose to an individual might prove the most effective strategy of preventing significant CIPN while assuring maximal anticancer effectiveness 124 . With respect to treatment of CIPN, a phase III random ized control trial favoured the use of duloxetine in patients with oxaliplatin or taxane-induced peripheral neuropathy; thus, data are available that support offering duloxetine to patients to minimize symptoms 122 . Fewer positive studies support the use of tricyclic antidepressants, gabapentin, and topical agents, including baclofen, amitriptyline, and ketamine, for the treatment of CIPN; however, ASCO guidelines suggest these may be effective for symptom management 122 , although none enhance neural repair. In other settings, such as diabetic neuropathy, gabapentin has been shown to be effective compared with placebo, but is most effective for redu cing pain and does not reduce the numbness or dys aesthesias that can be commonly experienced by affected patients [125] [126] [127] . In our experience, this pattern is also true in patients with CIPN.
The proteasome inhibitor bortezomib can induce peripheral neuropathy in 60-75% of patients receiving twice weekly therapy, and this neuropathy is severe with grade 3 or 4 toxicity noted in 15% of patients 128, 129 . The risk of neuropathy is decreased if the medication is administered via a subcutaneous rather than an intravenous route, if the drug is given weekly rather than twice weekly, and if the total dose is reduced 129 . The patients who tend to be at most risk of this adverse effect of bortezomib are those who have an underlying baseline neuropathy, which might be secondary to prior cancer treatment or the disease itself. The neuropathy occurs from damage to the dorsal root ganglia, and less commonly affects the axons. Patients typically present with painful, mild-to-moderate distal sensory neuropathy and occasionally they develop mild weakness in the legs (approximately 10% of patients) or autonomic symptoms, such as constipation and orthostatic hypotension. Patients are particularly susceptible to pressure-point neuropathies that can be super-imposed on the diffuse neuronal injury. Diagnostic workup reveals either demyelin ating or mixed axonal-demyelinating neuro pathy on nerve conduction studies, elevated levels of CSF protein, and sometimes contrast-enhancement of the nerve roots on MRI. Some patients respond to glucocorticoids or intravenous immunoglobulin, and some derive symptom improvement with topical menthol or agents for neuropathic pain, such as duloxetine 130 . Symptoms usually resolve within 3 months of discontinuing treatment; however, many patients are left with permanent sensory and motor deficits. Carfilzomib, a second-generation proteasome inhibitor, causes a much less severe neuropathy than bortezomib 131 . The antiangiogenic agents thalidomide, lenalidomide, and pomalidomide, can cause sensory peripheral neuro pathy. Neuropathy is most common in patients receiving thalidomide and is typically related to the duration, rather than the total dose, of treatment 132 . Patients complain of painful dysesthesias and sensory loss, but can also develop weakness, muscle cramps, fasciculations, and tremor. Autonomic manifestations include constipation and, rarely, impotence and bradycardia. At typical doses, 50% of patients taking thalidomide develop peripheral neuropathy (10% with severe symptoms), with an increased incidence in older patients 133 . Thalidomide-associated neuropathy is a common reason for dose reduction. With cessation of treatment, symptoms can be partially reversible, but can persist for over 1 year 132 . Lenalidomide is a second-generation, potent antiangiogenic agent that is much less neurotoxic than thalidomide. Likewise, pomalidomide and bevacizumab can occasionally cause neuropathy of mild severity 134, 135 .
Peripheral neuropathy from biological agents
Peripheral neuropathy is a common side effect of biological agents and immunotherapies. Brentuximab, an antibody against the CD30 marker found on B cells and T cells that is used to treat anaplastic large cell and refractory Hodgkin lymphoma, commonly causes peripheral neuropathy by disturbing axonal transport. Peripheral neuropathy occurs in 36-53% of patients, and is severe in 10-14% of patients 136 . The neuropathy is predominantly sensory with only 11% of patients experiencing motor symptoms 136 . The median time of onset is 27 weeks into treatment, and in 50% of patients, the symptoms improve and reverse completely within 3 months of treatment discontinuation 136 . Because the neuropathy is related to cumulative dose, treatment can be continued at a lower dose once the neuropathy improves to grade 1. Ado-trastuzumab, which is used to treat HER2-positive breast cancer in patients refractory to trastuzumab, can rarely cause a predominantly sensory neuropathy. In a study of 64,443 patients with adverse effects from trastuzumab, only 8 complained of neuropathy symptoms 137 . With respect to immunotherapy-related neuropathy, ipilimumab can induce autonomic neuropathy in approximately 1% of patients 138 . IFN-α can cause a distal sensory neuropathy that manifests with subjective pain and paresthesias and objective loss of pain and temperature sensation on examination 108 . IL-2 can cause a more focal neuropathy of the median nerve, which presents as a carpal tunnel syndrome with pain and sensory changes in the first three digits and palm of the hand 139 ; s ymptoms resolve with drug withdrawal.
Inflammatory demyelinating polyneuropathy
Ipilimumab can cause an acute inflammatory demyelinating polyneuropathy consistent with Guillain-Barre syndrome, which is thought to be triggered by crossreactivity of the stimulated T cells against Schwann cells that have antigens similar to those found on melanoma cells 140 ; the symptoms are identical to those seen with idio pathic Guillain-Barre with progressive sensory symptoms, ascending weakness, and respiratory insufficiency. CSF analysis often reveals elevated protein concentration without a pleocytosis (albuminocytologi cal dissociation) and electrophysiological studies show delayed nerve conduction velocities, increased distal motor latencies, and prolonged H-reflexes 141 . Treatment should include glucocorticoids to counteract the T-cell response in addition to standard intravenous i mmunoglobulin or plasmapheresis 5 . In addition to an acute inflammatory demyelinating polyneuropathy, ipilimumab rarely causes a chronic inflammatory demyelinating polyneuropathy (CIDP) 95 . Symptoms begin within 1 week of treatment and progress over weeks to months with sensory, motor, and autonomic changes and electrodiagnostic studies consistent with CIDP 95 . With cessation of treatment and plasmapheresis, neurological symptoms usually resolve in a matter of weeks 95 .
Neuromuscular junction defects
Some cancer treatments can induce a myasthenictype syndrome affecting the neuromuscular junction; these include cisplatin, IFN-α, IL-2 142 , and ipilimumab 95 . Symptoms include ptosis, diplopia, weakness, and respira tory difficulty and typically worsen with fatigue or repetitive activity. If the syndrome is treatment-induced, serum analysis for antibodies against the acetylcholine receptor will be negative. Electrophysiological examination demonstrates decremental responses with repetitive nerve stimulation identical to myasthenia gravis. Treatment can include discontinuing the offending agent, treating symptomatically with pyridostigmine, and initiating immuno modulatory treatment with p lasma pheresis or intravenous immunoglobulin.
Muscle symptoms
Myalgias are an adverse effect of both newer and older cancer treatments. Myalgias are common in patients treated with cisplatin, but also with several biologic agents, such as brentuximab and rituximab. Muscle cramps occur in 20-50% of patients receiving imatinib 143 . Rarely do patients develop elevated creatine kinase levels, muscle ooedema, or rhabdomyolysis 7 . Muscle cramps associated with these anticancer agents usually respond to supplementation with calcium, magnesium, or quinine.
Gemcitabine can cause an inflammatory myo pathy manifested by painful, focal weakness, typically of proximal muscles, that resolves with discontinuation of the drug; it also preferentially affects muscles contained in previously irradiated areas and in unusual locations, such as the abdominal wall 144 . Ipilimumab, along with causing inflammation of other organ systems, causes an inflammatory myopathy that can involve the facial muscles, pharyngeal muscles, or muscles of the extremities. IL-2 can also cause myositis. All inflammatory myopathies can result in elevated creatinine kinase levels and respond to steroids.
Whereas most myopathies affect the proximal muscles of the limbs, 'dropped head syndrome' is caused by isolated weakness of the neck extensors. The syndrome has been observed after exposure to selumetinib, a small-molecule inhibitor of MEK, which is used to treat melanoma and other solid tumours. Indeed, selumetinib can cause a focal non-inflammatory myopathy that is character ized by neck pain and neck extensor weakness 145 . Diagnostic workup reveals elevated creatine kinase levels as well abnormal 18 F-fluorodeoxyglucose uptake on PET imaging. As this adverse effect of selumetinib is noninflammatory, steroids are not helpful in the treatment of this syndrome and can actually exa cerbate myopathic symptoms. With discontinuation of the drug, the myopathy usually resolves. A similar syndrome occurs years after mantle radiotherapy for the treatment of Hodgkin lymphoma 146 . Clinically, patients develop reduced cervical range of motion, weakness of neck flexion and extension, and pain in the neck. EMG demonstrates amyo trophy of the neck and shoulder muscles, which is due to radiotherapy injury to the cervical nerves. No treatment reverses this problem and it can be slowly progressive.
Motor-neuron syndrome
Radiotherapy, typically to the pelvic region, or craniospinal irradiation can cause a rare motor-neuron syndrome that arises from 3 months to 23 years after treatment 147 . Patients present with the subacute onset of flaccid leg weakness that affects both proximal and distal muscles and is accompanied by atrophy, fasciculations, and areflexia. Typically, patients have preserved sensory and autonomic function. MRI scans can be normal or show enhancement of the spinal nerve roots. Nerve conduction studies show normal sensory and motor conduction velocities, but variable denervation and myokymia might be seen on EMG. Symptoms might be progressive or can stabilize over the course of several months to years.
Conclusions
As cancer treatments continue to develop, the mechanisms of neurotoxicity also evolve. Both traditional and newer cancer treatments cause significant neurological toxicity in the central and peripheral nervous systems, which can limit the course of treatment. Recognition of these symptoms as treatment-induced is important as drug discontinuation or dose-adjustment might prevent further neurological injury. Also, knowledge of these toxicities can help to differentiate treatmentrelated s ymptoms from progression of cancer into the nervous system.
